Skip to main content
Top
Published in: Endocrine 1/2013

01-02-2013 | Original Article

Increased expression of pro-angiogenic factors and vascularization in thyroid hyperfunctioning adenomas with and without TSH receptor activating mutations

Authors: Marilena Celano, Marialuisa Sponziello, Giovanni Tallini, Valentina Maggisano, Rocco Bruno, Mariavittoria Dima, Enrico Di Oto, Adriano Redler, Cosimo Durante, Rosario Sacco, Sebastiano Filetti, Diego Russo

Published in: Endocrine | Issue 1/2013

Login to get access

Abstract

Autonomously functioning thyroid nodules (AFTN) are known to receive an increased blood influx necessary to sustain their high rate of growth and hormone production. Here, we investigated the expression of hematic and lymphatic vases in a series of 20 AFTN compared with the contralateral non-tumor tissues of the same patients, and the transcript levels of proteins involved in the control of vascular proliferation, including the vascular endothelial growth factor (VEGF) and platelet-derived growth factors (PDGF) and their receptors and the endothelial nitric oxide synthase (eNOS). In parallel, the expression of the differentiation markers sodium/iodide symporter (NIS), thyroperoxidase (TPO), thyroglobulin (Tg), and TSH receptor (TSHR) was also investigated. The data were further analyzed comparing subgroups of tumors with or without mutations in the TSHR gene. Analysis by means of CD31 and D2-40 immunostaining showed in AFTN an increased number of hematic, but not lymphatic, vessels in parallel with an enhanced proliferation rate shown by increased Ki67 staining. Quantitative RT-PCR analysis revealed an increase of VEGF, VEGFR1 and 2, PDGF-A, PDGF-B, and eNOS expression in tumor versus normal tissues. Also, higher transcript levels of NIS, TPO, and Tg were detected. Comparison of the two subgroups of samples revealed only few differences in the expression of the genes examined. In conclusion, these data demonstrate an increased expression of angiogenesis-related factors associated with an enhanced proliferation of hematic, but not lymphatic, vessels in AFTNs. In this context, the presence of TSHR mutations may only slightly influence the expression of pro-angiogenic growth factors.
Literature
1.
go back to reference R.S. Bahn Chair, H.B. Burch, D.S. Cooper, J.R. Garber, M.C. Greenlee, I. Klein, P. Laurberg, I.R. McDougall, V.M. Montori, S.A. Rivkees, D.S. Ross, J.A. Sosa, M.N. Stan, American Thyroid Association, American Association of Clinical Endocrinologists, Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 21(6) 593–646 (2011) Erratum in: Thyroid 21(10) 1169 (2011) R.S. Bahn Chair, H.B. Burch, D.S. Cooper, J.R. Garber, M.C. Greenlee, I. Klein, P. Laurberg, I.R. McDougall, V.M. Montori, S.A. Rivkees, D.S. Ross, J.A. Sosa, M.N. Stan, American Thyroid Association, American Association of Clinical Endocrinologists, Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 21(6) 593–646 (2011) Erratum in: Thyroid 21(10) 1169 (2011)
2.
go back to reference D. Russo, F. Arturi, E. Chiefari, S. Filetti, Molecular insights into TSH receptor abnormality and thyroid disease. J. Endocrinol. Invest. 20(1), 36–47 (1997)PubMed D. Russo, F. Arturi, E. Chiefari, S. Filetti, Molecular insights into TSH receptor abnormality and thyroid disease. J. Endocrinol. Invest. 20(1), 36–47 (1997)PubMed
3.
go back to reference A. Hébrant, W.C. van Staveren, C. Maenhaut, J.E. Dumont, J. Leclère, Genetic hyperthyroidism: hyperthyroidism due to activating TSHR mutations. Eur. J. Endocrinol. 164(1), 1–9 (2011)PubMedCrossRef A. Hébrant, W.C. van Staveren, C. Maenhaut, J.E. Dumont, J. Leclère, Genetic hyperthyroidism: hyperthyroidism due to activating TSHR mutations. Eur. J. Endocrinol. 164(1), 1–9 (2011)PubMedCrossRef
4.
go back to reference F. Arturi, D. Scarpelli, A. Coco, R. Sacco, R. Bruno, S. Filetti, D. Russo, TSH receptor mutations and thyroid hyperfunctioning adenomas 10 years after their first discovery: unresolved questions. Thyroid 13(4), 341–343 (2003)PubMedCrossRef F. Arturi, D. Scarpelli, A. Coco, R. Sacco, R. Bruno, S. Filetti, D. Russo, TSH receptor mutations and thyroid hyperfunctioning adenomas 10 years after their first discovery: unresolved questions. Thyroid 13(4), 341–343 (2003)PubMedCrossRef
5.
go back to reference D. Russo, M.G. Wong, G. Costante, E. Chiefari, P.A. Treseler, F. Arturi, S. Filetti, O.H. Clark, A Val 677 activating mutation of the thyrotropin receptor in a Hürthle cell thyroid carcinoma associated with thyrotoxicosis. Thyroid 9(1), 13–17 (1999)PubMedCrossRef D. Russo, M.G. Wong, G. Costante, E. Chiefari, P.A. Treseler, F. Arturi, S. Filetti, O.H. Clark, A Val 677 activating mutation of the thyrotropin receptor in a Hürthle cell thyroid carcinoma associated with thyrotoxicosis. Thyroid 9(1), 13–17 (1999)PubMedCrossRef
6.
go back to reference D. Russo, C. Betterle, F. Arturi, E. Chiefari, M.E. Girelli, S. Filetti, A novel mutation in the thyrotropin receptor gene causing loss of TSH binding but constitutive receptor activation in a family with resistance to TSH. J. Clin. Endocrinol. Metab. 85(11), 4238–4242 (2000)PubMedCrossRef D. Russo, C. Betterle, F. Arturi, E. Chiefari, M.E. Girelli, S. Filetti, A novel mutation in the thyrotropin receptor gene causing loss of TSH binding but constitutive receptor activation in a family with resistance to TSH. J. Clin. Endocrinol. Metab. 85(11), 4238–4242 (2000)PubMedCrossRef
7.
go back to reference N. Garcia de la Torre, I. Buley, J.A.H. Wass, H.E. Turner, Angiogenesis and lymphangiogenesis in thyroid proliferative lesions: relationship to type and tumor behaviour. Endocr. Relat. Cancer 13(3), 931–944 (2006)PubMedCrossRef N. Garcia de la Torre, I. Buley, J.A.H. Wass, H.E. Turner, Angiogenesis and lymphangiogenesis in thyroid proliferative lesions: relationship to type and tumor behaviour. Endocr. Relat. Cancer 13(3), 931–944 (2006)PubMedCrossRef
8.
go back to reference P. Viacava, G. Bocci, M. Tonnacchera, G. Fanelli, M. De Servi, P. Agretti, E. Berti, O. Goletti, P. Aretini, M.L. Resta, G. Bevilacqua, A.G. Naccarato, Markers of cell proliferation, apoptosis, and angiogenesis in thyroid adenomas: a comparative immunohistochemical and genetic investigation of functioning and nonfunctioning nodules. Thyroid 17(3), 191–197 (2007)PubMedCrossRef P. Viacava, G. Bocci, M. Tonnacchera, G. Fanelli, M. De Servi, P. Agretti, E. Berti, O. Goletti, P. Aretini, M.L. Resta, G. Bevilacqua, A.G. Naccarato, Markers of cell proliferation, apoptosis, and angiogenesis in thyroid adenomas: a comparative immunohistochemical and genetic investigation of functioning and nonfunctioning nodules. Thyroid 17(3), 191–197 (2007)PubMedCrossRef
9.
go back to reference M. Eszlinger, K. Krohn, R. Paschke, Complementary DNA expression array analysis suggests a lower expression of signal transduction proteins and receptors in cold and hot thyroid nodules. J. Clin. Endocrinol. Metab. 86(10), 4834–4842 (2001)PubMedCrossRef M. Eszlinger, K. Krohn, R. Paschke, Complementary DNA expression array analysis suggests a lower expression of signal transduction proteins and receptors in cold and hot thyroid nodules. J. Clin. Endocrinol. Metab. 86(10), 4834–4842 (2001)PubMedCrossRef
10.
go back to reference M. Capezzone, E. Morabito, P. Belletti, P. Giannasio, D. De Sanctis, R. Bruno, Increasing incidence of thyroid cancer in Basilicata: an Italian study. J. Endocrinol. Invest. 30(6), 507–512 (2007)PubMed M. Capezzone, E. Morabito, P. Belletti, P. Giannasio, D. De Sanctis, R. Bruno, Increasing incidence of thyroid cancer in Basilicata: an Italian study. J. Endocrinol. Invest. 30(6), 507–512 (2007)PubMed
11.
go back to reference D. Russo, S. Bulotta, R. Bruno, F. Arturi, P. Giannasio, M. Derwahl, J.M. Bidart, M. Schlumberger, S. Filetti, Sodium/iodide symporter (NIS) and pendrin are expressed differently in hot and cold nodules of thyroid toxic multinodular goiter. Eur. J. Endocrinol. 145(5), 591–596 (2001)PubMedCrossRef D. Russo, S. Bulotta, R. Bruno, F. Arturi, P. Giannasio, M. Derwahl, J.M. Bidart, M. Schlumberger, S. Filetti, Sodium/iodide symporter (NIS) and pendrin are expressed differently in hot and cold nodules of thyroid toxic multinodular goiter. Eur. J. Endocrinol. 145(5), 591–596 (2001)PubMedCrossRef
12.
go back to reference D. Russo, G. Costante, R. Bruno, M. Sponziello, G. Tamburrano, M. Dima, R. Sacco, L. Giacomelli, C. Durante, S. Filetti, TSH receptor extracellular region mutations in thyroid functioning nodules: further evidence for the functional role of this region in the receptor activation. Endocrine 40(3), 492–494 (2011)PubMedCrossRef D. Russo, G. Costante, R. Bruno, M. Sponziello, G. Tamburrano, M. Dima, R. Sacco, L. Giacomelli, C. Durante, S. Filetti, TSH receptor extracellular region mutations in thyroid functioning nodules: further evidence for the functional role of this region in the receptor activation. Endocrine 40(3), 492–494 (2011)PubMedCrossRef
13.
go back to reference M.L. Sponziello, R. Bruno, C. Durante, M. D’Agostino, R. Corradino, P. Giannasio, E. Ciociola, E. Ferretti, M. Maranghi, A. Verrienti, G. De Toma, S. Filetti, D. Russo, Growth factor receptors gene expression and Akt phosphorylation in benign human thyroid nodules are unaffected by chronic thyrotropin suppression. Horm. Metab. Res. 43(1), 22–25 (2011)PubMedCrossRef M.L. Sponziello, R. Bruno, C. Durante, M. D’Agostino, R. Corradino, P. Giannasio, E. Ciociola, E. Ferretti, M. Maranghi, A. Verrienti, G. De Toma, S. Filetti, D. Russo, Growth factor receptors gene expression and Akt phosphorylation in benign human thyroid nodules are unaffected by chronic thyrotropin suppression. Horm. Metab. Res. 43(1), 22–25 (2011)PubMedCrossRef
14.
go back to reference K.J. Livak, T.D. Schmittgen, Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCt method. Methods 25(4), 402–408 (2001)PubMedCrossRef K.J. Livak, T.D. Schmittgen, Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCt method. Methods 25(4), 402–408 (2001)PubMedCrossRef
15.
go back to reference C. Durante, G. Tallini, E. Puxeddu, M. Sponziello, S. Moretti, C. Logorio, A. Cavaliere, K.J. Rhoden, A. Verrienti, M. Maranghi, L. Giacomelli, D. Russo, S. Filetti, BRAF V600E mutation and expression of proangiogenic molecular markers in papillary thyroid carcinomas. Eur. J. Endocrinol. 165(3), 455–463 (2011)PubMedCrossRef C. Durante, G. Tallini, E. Puxeddu, M. Sponziello, S. Moretti, C. Logorio, A. Cavaliere, K.J. Rhoden, A. Verrienti, M. Maranghi, L. Giacomelli, D. Russo, S. Filetti, BRAF V600E mutation and expression of proangiogenic molecular markers in papillary thyroid carcinomas. Eur. J. Endocrinol. 165(3), 455–463 (2011)PubMedCrossRef
16.
go back to reference G. Tallini, G. Garcia-Rostan, A. Herrero, D. Zelterman, G. Viale, S. Bosari, M.L. Carcangiu, Downregulation of p27KIP1 and Ki67/Mib1 labeling index support the classification of thyroid carcinoma into prognostically relevant categories. Am. J. Surg. Pathol. 23(6), 678–685 (1999)PubMedCrossRef G. Tallini, G. Garcia-Rostan, A. Herrero, D. Zelterman, G. Viale, S. Bosari, M.L. Carcangiu, Downregulation of p27KIP1 and Ki67/Mib1 labeling index support the classification of thyroid carcinoma into prognostically relevant categories. Am. J. Surg. Pathol. 23(6), 678–685 (1999)PubMedCrossRef
17.
go back to reference M. D’Agostino, P. Voce, M. Celano, M. Sponziello, S. Moretti, V. Maggisano, A. Verrienti, C. Durante, S. Filetti, E. Puxeddu, D. Russo, Sunitinib exerts only limited effects on the proliferation and differentiation of anaplastic thyroid cancer cells. Thyroid 22(2), 138–144 (2012)PubMedCrossRef M. D’Agostino, P. Voce, M. Celano, M. Sponziello, S. Moretti, V. Maggisano, A. Verrienti, C. Durante, S. Filetti, E. Puxeddu, D. Russo, Sunitinib exerts only limited effects on the proliferation and differentiation of anaplastic thyroid cancer cells. Thyroid 22(2), 138–144 (2012)PubMedCrossRef
19.
go back to reference K.L. Kojic, S.L. Kojic, S.M. Wiseman, Differentiated thyroid cancers: a comprehensive review of novel targeted therapies. Expert Rev. Anticancer Ther. 12(3), 345–357 (2012)PubMedCrossRef K.L. Kojic, S.L. Kojic, S.M. Wiseman, Differentiated thyroid cancers: a comprehensive review of novel targeted therapies. Expert Rev. Anticancer Ther. 12(3), 345–357 (2012)PubMedCrossRef
20.
go back to reference G. Viglietto, A. Romano, G. Manzo, G. Chiappetta, I. Paoletti, D. Califano, M.G. Galati, V. Mauriello, P. Bruni, C.T. Lago, A. Fusco, M.G. Persico, Upregulation of the angiogenic factors PlGF, VEGF and their receptors (Flt-1, Flk-1/KDR) by TSH in cultured thyrocytes and in the thyroid gland of thiouracil-fed rats suggest a TSH-dependent paracrine mechanism for goiter hypervascularization. Oncogene 15(22), 2687–2698 (1997)PubMedCrossRef G. Viglietto, A. Romano, G. Manzo, G. Chiappetta, I. Paoletti, D. Califano, M.G. Galati, V. Mauriello, P. Bruni, C.T. Lago, A. Fusco, M.G. Persico, Upregulation of the angiogenic factors PlGF, VEGF and their receptors (Flt-1, Flk-1/KDR) by TSH in cultured thyrocytes and in the thyroid gland of thiouracil-fed rats suggest a TSH-dependent paracrine mechanism for goiter hypervascularization. Oncogene 15(22), 2687–2698 (1997)PubMedCrossRef
21.
go back to reference A. Jebreel, J. England, K. Bedford, J. Murphy, L. Karsai, S. Atkin, Vascular endothelial growth factor (VEGF), VEGF receptors expression and microvascular density in benign and malignant thyroid diseases. Int. J. Exp. Pathol. 88(4), 271–277 (2007)PubMedCrossRef A. Jebreel, J. England, K. Bedford, J. Murphy, L. Karsai, S. Atkin, Vascular endothelial growth factor (VEGF), VEGF receptors expression and microvascular density in benign and malignant thyroid diseases. Int. J. Exp. Pathol. 88(4), 271–277 (2007)PubMedCrossRef
22.
go back to reference K. Sato, K. Yamazaki, K. Shizume, Y. Kanaji, T. Obara, K. Ohsumi, H. Demura, S. Yamaguchi, M. Shibuya, Stimulation by thyroid-stimulating hormone and Grave’s immunoglobulin G of vascular endothelial growth factor mRNA expression in human thyroid follicles in vitro and flt mRNA expression in the rat thyroid in vivo. J. Clin. Invest. 96(3), 1295–1302 (1995)PubMedCrossRef K. Sato, K. Yamazaki, K. Shizume, Y. Kanaji, T. Obara, K. Ohsumi, H. Demura, S. Yamaguchi, M. Shibuya, Stimulation by thyroid-stimulating hormone and Grave’s immunoglobulin G of vascular endothelial growth factor mRNA expression in human thyroid follicles in vitro and flt mRNA expression in the rat thyroid in vivo. J. Clin. Invest. 96(3), 1295–1302 (1995)PubMedCrossRef
23.
go back to reference S. Hoffmann, L.C. Hofbauer, V. Scharrenbach, A. Wunderlich, I. Hassan, S. Lingelbach, A. Zielke, Thyrotropin (TSH)-induced production of vascular endothelial growth factor in thyroid cancer cells in vitro: evaluation of TSH signal transduction and of angiogenesis-stimulating growth factors. J. Clin. Endocrinol. Metab. 89(12), 6139–6145 (2004)PubMedCrossRef S. Hoffmann, L.C. Hofbauer, V. Scharrenbach, A. Wunderlich, I. Hassan, S. Lingelbach, A. Zielke, Thyrotropin (TSH)-induced production of vascular endothelial growth factor in thyroid cancer cells in vitro: evaluation of TSH signal transduction and of angiogenesis-stimulating growth factors. J. Clin. Endocrinol. Metab. 89(12), 6139–6145 (2004)PubMedCrossRef
24.
go back to reference S. Deleu, Y. Allory, A. Radulescu, I. Pirson, N. Carrasco, B. Corvilain, I. Salmon, B. Franc, J.E. Dumont, J. Van Sande, C. Maenhaut, Characterization of autonomous thyroid adenoma: metabolism, gene expression, and pathology. Thyroid 10(2) 131–140 (2000). Erratum in: Thyroid 2001 Jun; 11(6): following 609 S. Deleu, Y. Allory, A. Radulescu, I. Pirson, N. Carrasco, B. Corvilain, I. Salmon, B. Franc, J.E. Dumont, J. Van Sande, C. Maenhaut, Characterization of autonomous thyroid adenoma: metabolism, gene expression, and pathology. Thyroid 10(2) 131–140 (2000). Erratum in: Thyroid 2001 Jun; 11(6): following 609
25.
go back to reference F.T. Hall, J.L. Freeman, S.L. Asa, D.G. Jackson, N.J. Beasley, Intratumoral lymphatics and lymph node metastases in papillary thyroid carcinoma. Arch. Otolaryngol. Head Neck Surg. 129(7), 716–719 (2003)PubMedCrossRef F.T. Hall, J.L. Freeman, S.L. Asa, D.G. Jackson, N.J. Beasley, Intratumoral lymphatics and lymph node metastases in papillary thyroid carcinoma. Arch. Otolaryngol. Head Neck Surg. 129(7), 716–719 (2003)PubMedCrossRef
26.
go back to reference I.M. Colin, E. Nava, D. Toussaint, D.M. Maiter, M.F. van Denhove, T.F. Lüscher, J.M. Ketelslegers, J.F. Denef, J.L. Jameson, Expression of nitric oxide synthase isoforms in the thyroid gland: evidence for a role of nitric oxide in vascular control during goiter formation. Endocrinology 136(12), 5283–5290 (1995)PubMedCrossRef I.M. Colin, E. Nava, D. Toussaint, D.M. Maiter, M.F. van Denhove, T.F. Lüscher, J.M. Ketelslegers, J.F. Denef, J.L. Jameson, Expression of nitric oxide synthase isoforms in the thyroid gland: evidence for a role of nitric oxide in vascular control during goiter formation. Endocrinology 136(12), 5283–5290 (1995)PubMedCrossRef
27.
go back to reference I.M. Colin, P. Kopp, J. Zbären, A. Häberli, W.E. Grizzle, J.L. Jameson, Expression of nitric oxide synthase III in human thyroid follicular cells: evidence for increased expression in hyperthyroidism. Eur. J. Endocrinol. 136(6), 649–655 (1997)PubMedCrossRef I.M. Colin, P. Kopp, J. Zbären, A. Häberli, W.E. Grizzle, J.L. Jameson, Expression of nitric oxide synthase III in human thyroid follicular cells: evidence for increased expression in hyperthyroidism. Eur. J. Endocrinol. 136(6), 649–655 (1997)PubMedCrossRef
28.
go back to reference J.E. Donckier, L. Michel, M. Delos, X. Havaux, R. Van Beneden, Interrelated overexpression of endothelial and inducible nitric oxide synthases, endothelin-1 and angiogenic factors in human papillary thyroid carcinoma. Clin. Endocrinol. (Oxf) 64(6), 703–710 (2006)CrossRef J.E. Donckier, L. Michel, M. Delos, X. Havaux, R. Van Beneden, Interrelated overexpression of endothelial and inducible nitric oxide synthases, endothelin-1 and angiogenic factors in human papillary thyroid carcinoma. Clin. Endocrinol. (Oxf) 64(6), 703–710 (2006)CrossRef
29.
go back to reference M. Celano, F. Arturi, I. Presta, R. Bruno, D. Scarpelli, M.G. Calvagno, C. Cristofaro, S. Bulotta, P. Giannasio, R. Sacco, S. Filetti, D. Russo, Expression of adenylyl cyclase types III and VI in human hyperfunctioning thyroid nodules. Mol. Cell. Endocrinol. 203(1–2), 129–135 (2003)PubMedCrossRef M. Celano, F. Arturi, I. Presta, R. Bruno, D. Scarpelli, M.G. Calvagno, C. Cristofaro, S. Bulotta, P. Giannasio, R. Sacco, S. Filetti, D. Russo, Expression of adenylyl cyclase types III and VI in human hyperfunctioning thyroid nodules. Mol. Cell. Endocrinol. 203(1–2), 129–135 (2003)PubMedCrossRef
30.
go back to reference L. Persani, A. Lania, L. Alberti, R. Romoli, G. Mantovani, S. Filetti, A. Spada, M. Conti, Induction of specific phosphodiesterase isoforms by constitutive activation of the cAMP pathway in autonomous thyroid adenomas. J. Clin. Endocrinol. Metab. 85(8), 2872–2878 (2000)PubMedCrossRef L. Persani, A. Lania, L. Alberti, R. Romoli, G. Mantovani, S. Filetti, A. Spada, M. Conti, Induction of specific phosphodiesterase isoforms by constitutive activation of the cAMP pathway in autonomous thyroid adenomas. J. Clin. Endocrinol. Metab. 85(8), 2872–2878 (2000)PubMedCrossRef
31.
go back to reference A. Brunetti, E. Chiefari, S. Filetti, D. Russo, The cyclic AMP response elements binding protein (CREB) is functionally reduced in human toxic thyroid adenomas. Endocrinology 141(2), 722–730 (2000)PubMedCrossRef A. Brunetti, E. Chiefari, S. Filetti, D. Russo, The cyclic AMP response elements binding protein (CREB) is functionally reduced in human toxic thyroid adenomas. Endocrinology 141(2), 722–730 (2000)PubMedCrossRef
32.
go back to reference F. Arturi, C. Capula, E. Chiefari, S. Filetti, D. Russo, Thyroid hyperfunctioning adenomas with and without Gsp/TSH receptor mutations show similar clinical features. Exp. Clin. Endocrinol. Diabetes 106(3), 234–236 (1998)PubMedCrossRef F. Arturi, C. Capula, E. Chiefari, S. Filetti, D. Russo, Thyroid hyperfunctioning adenomas with and without Gsp/TSH receptor mutations show similar clinical features. Exp. Clin. Endocrinol. Diabetes 106(3), 234–236 (1998)PubMedCrossRef
33.
go back to reference E. Puxeddu, S. Romagnoli, M.E. Dottorini, Targeted therapies for advanced thyroid cancer. Curr. Opin. Oncol. 23(1), 13–21 (2011)PubMedCrossRef E. Puxeddu, S. Romagnoli, M.E. Dottorini, Targeted therapies for advanced thyroid cancer. Curr. Opin. Oncol. 23(1), 13–21 (2011)PubMedCrossRef
34.
go back to reference B. Corvilain, J. Van Sande, J.E. Dumont, G. Vassart, Somatic and germline mutations of the TSH receptor and thyroid diseases. Clin. Endocrinol. (Oxf.) 55(2), 143–158 (2001) B. Corvilain, J. Van Sande, J.E. Dumont, G. Vassart, Somatic and germline mutations of the TSH receptor and thyroid diseases. Clin. Endocrinol. (Oxf.) 55(2), 143–158 (2001)
35.
go back to reference E. Nishihara, C.R. Chen, Y. Mizutori-Sasai, M. Ito, S. Kubota, N. Amino, A. Miyauchi, B. Rapoport, Deletion of thyrotropin receptor residue Asp403 in a hyperfunctioning thyroid nodule provides insight into the role of the ectodomain in ligand-induced receptor activation. J. Endocrinol. Invest. 35(1), 49–53 (2012)PubMed E. Nishihara, C.R. Chen, Y. Mizutori-Sasai, M. Ito, S. Kubota, N. Amino, A. Miyauchi, B. Rapoport, Deletion of thyrotropin receptor residue Asp403 in a hyperfunctioning thyroid nodule provides insight into the role of the ectodomain in ligand-induced receptor activation. J. Endocrinol. Invest. 35(1), 49–53 (2012)PubMed
Metadata
Title
Increased expression of pro-angiogenic factors and vascularization in thyroid hyperfunctioning adenomas with and without TSH receptor activating mutations
Authors
Marilena Celano
Marialuisa Sponziello
Giovanni Tallini
Valentina Maggisano
Rocco Bruno
Mariavittoria Dima
Enrico Di Oto
Adriano Redler
Cosimo Durante
Rosario Sacco
Sebastiano Filetti
Diego Russo
Publication date
01-02-2013
Publisher
Springer US
Published in
Endocrine / Issue 1/2013
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-012-9747-3

Other articles of this Issue 1/2013

Endocrine 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.